This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
I participated in 2004 in the creation of the Bioméditerranée cluster foreshadowing the Eurobiomed competitiveness cluster, which is currently the catalyst of the health sector in the Provence-Alpes-Côte d’Azur and Languedoc-Roussillon regions with 400 companies, 8 Universities, 400 research centres, 4 University Hospitals Centres and one Interregional Clinical Research Organization.
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential. Marseille Immunopole is a perfect illustration of this approach and we are very proud of the magnitude taken today by this new operation initiated in 2013. Eurobiomed still remains very involved, animating the community and participating in the driving force that allows the creation of start-ups and the development of industrials and service companies in MI and the implementation of ambitious partnerships in France and internationally on these issues.#ecosystème
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.
AMU, IPC, CRCM
The Pioneer Project is unique as a strong public/private partnership between academia, a medical cancer center, 3 biotechs and a major pharma
Bernard A. FOX
Providence Cancer Institute, Portland, Oregon | UbiVac
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
AMU, IPC, CRCM
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.